GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of new data on the viscosity of several commercially available 10% intravenous immunoglobulin (IVIG) products at ...

A rare Guillain-Barré syndrome recurrence caused nausea with no motor symptoms but was treated successfully with intravenous ...

GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received ...

Panelists discuss how preparing multiple myeloma patients for treatment involves structured education, emotional support, and proactive symptom management—emphasizing clear communication about the ...

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...

Annexon offers speculative upside with Tanruprubart, targeting Guillain-Barré Syndrome's unmet needs. Click here to read my ...

The FDA has approved Gammagard Liquid ERC as a replacement therapy for PI in adult and pediatric patients 2 years of age and older.

Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...

Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) productsGC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical ...

Prince Edward Island's Chief Public Health Office says a total of 15 people have now been identified as at risk after ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of autologous anti-CD19 CAR T-cells.

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...